Global Inotropic Agents Market Size 2024, Forecast To 2033
6 Mar, 2024
The inotropic agents market size has grown rapidly in recent years. It will grow from $2.32 billion in 2023 to $2.59 billion in 2024 at a compound annual growth rate (CAGR) of 11.2%. The growth in the historic period can be attributed to education and awareness initiatives, expansion of cardiac treatment options, development of safer agents, improved patient outcomes, regulatory approvals. The inotropic agents market size is expected to see rapid growth in the next few years. It will grow to $4.01 billion in 2028 at a compound annual growth rate (CAGR) of 11.6%. The growth in the forecast period can be attributed to the growing cardiovascular disease burden, advancements in drug delivery systems, personalized medicine approach, increasing research funding, demand for combination therapies. Major trends in the forecast period include patient education and awareness, targeting cardiomyopathies, focus on heart failure management, combination therapies, improved safety profiles.
Global Inotropic Agents Market Key Driver
The surge in the prevalence of cardiovascular diseases is driving the inotropic agent market. Cardiovascular diseases (CVDs) refer to diseases of the vascular system and heart functioning. Inotropic agents are used in the treatment of cardiovascular diseases to improve the contractility and function of the heart, tackle cardiac shock, and slow the heart rate as they help the heart contract more powerfully, thereby increasing blood flow. So this helps boost the inotropic agent market. For instance, in October 2022, according to the reports shared by the Centers for Disease Control and Prevention, a US-based government agency, heart diseases were the leading cause of death in the US. About 697,000 people died from heart disease in 2020, which was roughly 1 in every 5 deaths. About 20.1 million adults were suffering from coronary artery disease. Each year, about 805,000 people in the US suffer from a heart attack. Furthermore, in August 2022, according to the American College of Cardiology, a US-based nonprofit medical association, the risk of stroke was expected to increase by 33.8 percent to 15 million from 2025 to 2060. Therefore, the surge in the prevalence of cardiovascular diseases is propelling the inotropic agent market forward. The market size of the inotropic agent market in 2023 was [insert 2023 market size], and it is projected to reach [insert 2024 market size] by 2024 and [insert 2028 market size] by 2028.
Get A Free Sample Of The Global Inotropic Agents Market ReportGlobal Inotropic Agents Market Segments
The inotropic agents market covered in this report is segmented –
1) By Type: Positive Inotropic Drugs, Negative Inotropic Drugs, Other Types
2) By Route Of Administration: Oral, Parenteral, Other Routes Of Administration
3) By Indication: Heart Attack, Heart Failure, Angina, Arrhythmia, Other Indications
4) By Distribution Channel: Hospital Pharmacy, Retail Pharmacy, Other Distribution Channels
5) By End User: Hospital, Homecare, Specialty Centers, Other End Users
By Geography:The regions covered in the inotropic agents market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain
North America was the largest region in the inotropic agents market in 2023. Asia-Pacific is expected to be the fastest-growing region in the global inotropic agents market report during the forecast period. The regions covered in the inotropic agents market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa
Major Inotropic Agents Industry Players
Pfizer Inc., GSK plc, Novartis AG, Mylan N.V., Boehringer Ingelheim International GmbH, AstraZeneca plc, Johnson & Johnson, Bayer AG, Merck & Co. Inc., Bristol-Myers Squibb Company, Cipla Ltd., Eli Lilly And Company, Sanofi S.A., Baxter International Inc., Hikma Pharmaceuticals plc, Sun Pharmaceuticals Industries Ltd., Cadila Pharmaceuticals Ltd., AbbVie Inc., Allergan plc, Amgen Inc., Daiichi Sankyo Company Limited, Eisai Co. Ltd., Fresenius Kabi AG, Genentech Inc., GlaxoSmithKline plc, Intas Pharmaceuticals Ltd., Lupin Limited, Regeneron Pharmaceuticals Inc., Roche Holding AG, BioNTech SE
Get The Full Global Inotropic Agents Market Report
Inotropic Agents Market Overview
Inotropic agents refer to a class of medications that affect the contractility of the heart muscle. They are used to treat conditions such as heart failure, where the heart is unable to pump enough blood to meet the body's needs. Inotropic agents work by increasing the strength and force of the heart's contractions, which can improve blood flow to the body's organs and tissues.
Inotropic Agents Global Market Report 2023 provides data on the global inotropic agents market such as market size, growth forecasts, segments and geographies, competitive landscape including leading competitors’ revenues, profiles and market shares. The inotropic agents market report identifies opportunities and strategies based on market trends and leading competitors’ approaches.